The Utilization of CRISPR/Cas9 in Monogenic Disorders Authors

Category

Health & Natural Sciences & Engineering > Natural Sciences > Kinesiology

Received

April 20, 2022

Accepted

August 19, 2022

Published

August 31, 2022

Authors

Shauna M. Mellor, University of Nevada, Las VegasFollow

Authors

Shauna M. Mellor (SMM)^1*

Author Affiliations

¹Department of Kinesiology and Nutrition Sciences, University of Nevada, Las Vegas, Las Vegas, NV, USA.

Corresponding Author

*Shauna M. Mellor, mellos1@unlv.nevada.edu

Corresponding Author ORCID iD

https://orcid.org/0000-0001-9070-6506

DOI

https://doi.org/10.9741/2766-7227.1018

Author Contributions

SMM: Literature review, context breakdown, data collection, drafting of paper, and manuscript revisions

Copyright

Articles in Spectra are freely available under a Creative Commons Attribution License (CC BY 4.0) which allows others to re-use the work without permission as long as the work is properly cited.

Data Availability Statement

The authors of this article confirm that all data underlying the findings are fully available without restrictions.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Ethical Considerations

Given that this project did not involve human or animal subjects, no IRB or IACUC approval was needed. All research was derived from publicly shared sources.

Abstract

This paper is a literature review of various scientific research papers, exploring the recent scientific advancement in the field of genetic engineering. The research presented is a foundational tool, building awareness on the implications of CRISPR/ Cas9 technology. CRISPR/ Cas9 was first discovered through the study of bacterial immune systems, fighting against viral infections. Manipulation of the Cas9 protein would eventually lead to target specific, gene-altering medicines for human organisms. CRISPR/ Cas 9 technology has begun to show promise as an effective treatment for certain monogenic disorders. Despite this, time is required before its efficacy as a proven genetic treatment plan. Certain drawbacks like chromosomal rearrangements and the formation of cancerous cells, reveal the potential negative consequences of CRISPR/Cas9 treatment. Careful calculations will be required to ensure the safety and specificity of this technology throughout future clinical trials.

Keywords

CRISPR/ Cas 9, gene editing, genetic engineering, DNA mutation, non homologous end joining, homologous directed repair, Intellia, CRISPR therapeutics, monogenic disorders

Submission Type

Primary review article

Recommended Citation

Mellor, S. M. (2022). The utilization of CRISPR/Cas9 in monogenic disorders. Spectra Undergraduate Research Journal, 2(2), 30-34.https://doi.org/10.9741/2766-7227.1018